moxifloxacin has been researched along with ritonavir in 14 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (ritonavir) | Trials (ritonavir) | Recent Studies (post-2010) (ritonavir) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 5,419 | 1,291 | 2,772 |
| Protein | Taxonomy | moxifloxacin (IC50) | ritonavir (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 6.1 | |
| Bile salt export pump | Homo sapiens (human) | 2.085 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.65 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.1623 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.3 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.458 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.067 | |
| Substance-K receptor | Homo sapiens (human) | 2.622 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 2.35 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.076 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 4.4 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.1933 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.4 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2 | |
| Protease | Human immunodeficiency virus 1 | 4.9253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 7 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Caceres, M; Devinsky, O; Huddlestone, JR; Kasserra, C; Medlock, M; Morrison, R; O'Mara, E; Soni, P; Wan, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amantea, MA; Nickens, DJ; Raber, SR; Reynolds, RR; Sarapa, N | 1 |
| Cristea, L; Farha, R; Jordan, P; Kolis, S; Lee, LS; Salgo, M; Zhang, X | 1 |
| Cao, Y; Xu, S; Zhou, M; Zhu, F | 1 |
| Chen, Q; Dai, Y; Gao, G; Han, W; Li, J; Li, L; Li, X; Liu, C; Quan, B; Wang, C; Yang, J; Zhang, G; Zhang, J; Zhang, Z; Zheng, W | 1 |
| Chen, T; Hu, Y; Li, L; Liu, H; Liu, M; Wang, F; Wang, Y; Xia, H; Zhang, L; Zhao, S | 1 |
| Cao, J; Fan, L; He, F; Hu, K; Lei, M; Luo, Q; Qin, S; Shao, X; Yang, L; Yu, N | 1 |
| Luo, S; Tian, M; Wang, L; Xia, W; Zeng, Y; Zha, Y; Zhang, K; Zhang, X | 1 |
| Chen, Y; Fan, L; Gu, Y; Li, N; Liu, C; Liu, H; Liu, Y | 1 |
| Tang, L; Zeng, X | 1 |
2 review(s) available for moxifloxacin and ritonavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lopinavir; Lung; Lupus Erythematosus, Systemic; Moxifloxacin; Mycophenolic Acid; Pandemics; Pneumonia, Viral; Prednisone; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
3 trial(s) available for moxifloxacin and ritonavir
| Article | Year |
|---|---|
Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; Arrhythmias, Cardiac; CCR5 Receptor Antagonists; Central Nervous System; Electrocardiography; Electroencephalography; Female; Heart; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyrimidines; Ritonavir; Young Adult | 2010 |
Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
Topics: Adult; Aza Compounds; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Drug Therapy, Combination; Electrocardiography; Female; Fluoroquinolones; Heart Rate; HIV Protease Inhibitors; Humans; Imidazoles; Ketoconazole; Liver; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Reference Values; Reproducibility of Results; Research Design; Reverse Transcriptase Inhibitors; Ritonavir; Sulfur Compounds; Treatment Outcome | 2008 |
Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants.
Topics: Adolescent; Adult; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Fluoroquinolones; HIV Protease Inhibitors; Humans; Least-Squares Analysis; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Ritonavir; Saquinavir; Torsades de Pointes; Young Adult | 2012 |
9 other study(ies) available for moxifloxacin and ritonavir
| Article | Year |
|---|---|
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
Topics: Anti-HIV Agents; Betacoronavirus; China; Clinical Laboratory Techniques; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Testing; Diabetes Mellitus, Type 2; Drug Combinations; gamma-Globulins; HIV; HIV Infections; Humans; Lopinavir; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019.
Topics: Adolescent; Adult; Betacoronavirus; China; Clinical Laboratory Techniques; Contact Tracing; Coronavirus Infections; COVID-19; COVID-19 Testing; Female; Humans; Interferon alpha-2; Lopinavir; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Oropharynx; Oxygen; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; T-Lymphocytes; Tomography, X-Ray Computed | 2020 |
Positive detection of SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid in tear and conjunctival secretions of a non-conjunctivitis COVID-19 patient with obstruction of common lacrimal duct.
Topics: Aged; Anti-Bacterial Agents; Conjunctiva; Conjunctivitis, Viral; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Eye Infections, Viral; Flow Cytometry; Herpes Simplex; Herpesvirus 1, Human; Herpesvirus 6, Human; High-Throughput Nucleotide Sequencing; HIV Protease Inhibitors; Humans; Lacrimal Duct Obstruction; Lopinavir; Male; Medicine, Chinese Traditional; Moxifloxacin; Nasopharynx; Nucleic Acids; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Roseolovirus Infections; SARS-CoV-2; Tears | 2020 |
The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Indoles; Lopinavir; Medicine, Chinese Traditional; Methylprednisolone; Middle Aged; Moxifloxacin; Noninvasive Ventilation; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Qi; Ritonavir; SARS-CoV-2 | 2020 |
Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: A single-center, retrospective, observational study.
Topics: Anti-Bacterial Agents; Antiviral Agents; China; COVID-19 Drug Treatment; Female; Glucocorticoids; Humans; Immunologic Factors; Indoles; Linezolid; Lopinavir; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Ritonavir | 2021 |
One-year Follow-up after Severe SARS-CoV-2 Pneumonia.
Topics: Anti-Bacterial Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Follow-Up Studies; Humans; Lung; Middle Aged; Moxifloxacin; Ritonavir; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed | 2021 |